, suggesting markets were set for another seesaw day driven by uncertainty regarding the potential impact of the Omicron Covid-19 variant. :
Shares of Vir Biotechnology jumped almost 10% premarket after a Covid-19 antibody treatment developed by it and GlaxoSmithKline was effective against the Omicron variant in early laboratory studies, the companies said, setting it apart from similar therapies that appear to work less well against the highly mutated strain.
, including its latest one, and that management has concluded there was a material weakness in its internal control.that the company told suppliers that demand for the iPhone 13 lineup has weakened.
do ESG revolution! do ESG blockchain revolution!
ประเทศไทย ข่าวล่าสุด, ประเทศไทย หัวข้อข่าว
Similar News:คุณยังสามารถอ่านข่าวที่คล้ายกันนี้ซึ่งเรารวบรวมจากแหล่งข่าวอื่น ๆ ได้
European stocks drop as Omicron fears keep markets on edgeEuropean stock indexes opened lower on Thursday, reversing gains from the previous session as a lack of information about the Omicron variant of COVID-19 left markets volatile, and as investors also bet on faster Fed tapering.
อ่านเพิ่มเติม »
Here’s What Wall Street’s Biggest Banks Predict For Stocks In 2022—And What To Watch ForMost forecasts remain cautiously optimistic about the market’s prospects next year but warn of below average returns.
อ่านเพิ่มเติม »
How to save corals by applying stock market investment strategiesCoral reefs are in danger, with at least 14 percent having died in the last decade. But now, scientists believe they can apply a Nobel Prize winning theory to save them.
อ่านเพิ่มเติม »